ライフサイエンスコーパス: cardiopulmonary bypass

1 ct to treatment assignment (OPCAB or CABG on cardiopulmonary bypass).

2 nction in patients after cardiac surgery and cardiopulmonary bypass.

3 verse events after cardiac surgery requiring cardiopulmonary bypass.

4 h risk of morbidity and mortality undergoing cardiopulmonary bypass.

5 rdiopulmonary physiology and the sequelae of cardiopulmonary bypass.

6 rombocytopenic and have cardiac surgery with cardiopulmonary bypass.

7 f methylprednisolone for patients undergoing cardiopulmonary bypass.

8 corporeal membrane oxygenation compared with cardiopulmonary bypass.

9 r major morbidity after cardiac surgery with cardiopulmonary bypass.

10 h risk of morbidity and mortality undergoing cardiopulmonary bypass.

11 frequently occur after cardiac surgery with cardiopulmonary bypass.

12 were hemodynamically stable with no need for cardiopulmonary bypass.

13 in patients undergoing cardiac surgery with cardiopulmonary bypass.

14 d lower in the sepsis group during and after cardiopulmonary bypass.

15 lving inflammatory response during and after cardiopulmonary bypass.

16 mean arterial blood pressure targets during cardiopulmonary bypass.

17 extraction, early after cardiac surgery with cardiopulmonary bypass.

18 infants undergoing surgery with and without cardiopulmonary bypass.

19 ngenital heart disease both with and without cardiopulmonary bypass.

20 similar rates after surgery with or without cardiopulmonary bypass.

21 ily on methods of vital organ support during cardiopulmonary bypass.

22 to 36 months of age, undergoing surgery with cardiopulmonary bypass.

23 al circulatory arrest or continuous low-flow cardiopulmonary bypass.

24 e elective, and almost all patients required cardiopulmonary bypass.

25 al management strategies for separation from cardiopulmonary bypass.

26 in in group B was 104 +/- 160 at 4 hrs after cardiopulmonary bypass.

27 from cardiopulmonary bypass or use to avoid cardiopulmonary bypass.

28 ed management of cerebral oxygenation during cardiopulmonary bypass.

29 rSo(2) during the 60-minute period following cardiopulmonary bypass.

30 evels decrease in infants and children after cardiopulmonary bypass.

31 25 at 4, 24, and 48 hrs, respectively, after cardiopulmonary bypass.

32 s to achieve separation from or avoidance of cardiopulmonary bypass.

33 d no acute conversion to surgery or need for cardiopulmonary bypass.

34 an 2 years old undergoing heart surgery with cardiopulmonary bypass.

35 with group B before and 24 and 48 hrs after cardiopulmonary bypass.

36 deep hypothermic circulatory arrest or even cardiopulmonary bypass.

37 an their racial counterparts who had CABG on cardiopulmonary bypass.

38 al echocardiography, cardiac surgery, and/or cardiopulmonary bypass.

39 ms obtained during initiation and weaning of cardiopulmonary bypass.

40 ll with cardiac arrest and longer periods of cardiopulmonary bypass.

41 yocardial arrest and reperfusion achieved by cardiopulmonary bypass.

42 ine after CABG is not specific to the use of cardiopulmonary bypass.

43 preservation, followed by resuscitation with cardiopulmonary bypass.

44 after the induction of anesthesia and before cardiopulmonary bypass.

45 heart valve interventions without the use of cardiopulmonary bypass.

46 o attenuate the coagulopathy associated with cardiopulmonary bypass.

47 ollowed by 20 mins of EPR using miniaturized cardiopulmonary bypass.

48 ary revascularization without utilization of cardiopulmonary bypass.

49 for each ordered dose within 24 hours after cardiopulmonary bypass.

50 e onset of immunoparalysis in the setting of cardiopulmonary bypass.

51 hile patient is hemodynamically supported on cardiopulmonary bypass.

52 e undergoing cardiac surgery with the use of cardiopulmonary bypass.

53 ples before and after the ischemic insult of cardiopulmonary bypass.

54 drome in 31.3%, and 95.2% of procedures used cardiopulmonary bypass.

55 e undergoing cardiac surgery with the use of cardiopulmonary bypass.

56 patients who underwent cardiac surgery with cardiopulmonary bypass.

57 hours, and 18-24 hours after separation from cardiopulmonary bypass.

58 on to conventional surgery (0.6%) and use of cardiopulmonary bypass (0.7%) were rare.

59 The overall rate of LOF was 4.3% (return to cardiopulmonary bypass, 2.6%; intraaortic balloon pumps,

60 3) and during the 60-minute period following cardiopulmonary bypass (65+/-11% versus 75+/-10%, P=0.00

61 rSo(2) from postinduction to 60 minutes post cardiopulmonary bypass (71+/-10% versus 78+/-6%, P=0.01)

62 ion harvesting (98.9%, 66.0%, and 68.1%) and cardiopulmonary bypass (83.4%, 45%, and 36.9%) were less

63 Right atrial biopsies were collected before cardiopulmonary bypass and 10 minutes after aortic cross

64 Blood samples were collected before cardiopulmonary bypass and 4, 24, and 48 hrs after cardi

65 pg/mL) for all patients was 21 +/- 63 before cardiopulmonary bypass and 80 +/- 145, 43 +/- 79, and 19

66 Median cardiopulmonary bypass and aortic cross-clamp times were

67 high risk for complications associated with cardiopulmonary bypass and aortic manipulation.

68 ular stroke work index was examined prior to cardiopulmonary bypass and at 24 hours reperfusion.

69 opolysaccharide group but only at the end of cardiopulmonary bypass and beginning of postbypass (p <

70 ize the morbidity associated with the use of cardiopulmonary bypass and circulatory arrest in patient

71 Cardiac surgery, especially when employing cardiopulmonary bypass and deep hypothermic circulatory

72 ficant difference was found between low-flow cardiopulmonary bypass and deep hypothermic circulatory

73 th ischemia and reperfusion injury following cardiopulmonary bypass and deep hypothermic circulatory

74 inotropes, and RBC transfusion starting from cardiopulmonary bypass and ending 8 hours after arrival

75 ed for nonemergent cardiac surgery requiring cardiopulmonary bypass and had recognized risk factors f

76 xcellent, this technique requires the use of cardiopulmonary bypass and is associated with protracted

77 Generation of plasma hemoglobin during cardiopulmonary bypass and male gender are associated wi

78 thout cardiac arrest, followed by 60 mins of cardiopulmonary bypass and mechanical ventilation.

79 in-induced thrombocytopenia in patients post cardiopulmonary bypass and on extracorporeal membrane ox

80 uggested that CABG techniques that eliminate cardiopulmonary bypass and reduce aortic manipulation ma

81 ssue obtained from patients before and after cardiopulmonary bypass and reperfusion and left ventricu

82 Here we investigated the effect of cardiopulmonary bypass and reperfusion on myocardial nit

83 ry to attenuate the inflammatory response to cardiopulmonary bypass and surgical trauma; however, evi

84 ney injury) in high-risk patients undergoing cardiopulmonary bypass and that the protective effect is

85 ified in the lipopolysaccharide group during cardiopulmonary bypass and the postbypass period (p < 0.

86 Levels of plasma hemoglobin increased during cardiopulmonary bypass and were associated (p < 0.01) wi

87 s between intervention (ie, after removal of cardiopulmonary bypass) and closure of chest.

88 line (in a subset), the beginning and end of cardiopulmonary bypass, and 2 hours and 24 hours after c

89 uits of heater-cooler units connected to the cardiopulmonary bypass, and air samples collected when t

90 have been introduced to minimize exposure to cardiopulmonary bypass, and improve outcomes for these h

91 ure, avoidance of the detrimental effects of cardiopulmonary bypass, and larger effective orifice are

92 re of injury, type of repair, utilization of cardiopulmonary bypass, and outcome.

93 of coronary artery disease, prolonged use of cardiopulmonary bypass, and severe primary graft dysfunc

94 Ten swine underwent a 90-minute cardiopulmonary bypass, and surveillance was maintained

95 Conventional MV surgery requires cardiopulmonary bypass, aortic cross-clamping, cardiople

96 and repair on an arrested heart, but require cardiopulmonary bypass, aortic cross-clamping, sternotom

97 We also showed that the use of cardiopulmonary bypass assistance may help alleviate som

98 igations were pursued: (1) identification of cardiopulmonary bypass-associated M. chimaera infection

99 Eighteen probable cases of cardiopulmonary bypass-associated M. chimaera infection

100 ive patients undergoing cardiac surgery with cardiopulmonary bypass at 12 hospitals from October 6, 2

101 Neonates undergoing cardiac surgery with cardiopulmonary bypass at 2 centers were enrolled in a d

102 ars or older undergoing cardiac surgery with cardiopulmonary bypass at 8 cardiac surgical centers in

103 n, the hepatic resection was performed under cardiopulmonary bypass because of extended vena cava thr

104 nd cooled to 16 degrees C to 18 degrees C on cardiopulmonary bypass before instituting deep hypotherm

105 ronary artery bypass graft-only surgery with cardiopulmonary bypass between August 2001 and May 2005.

106 04) rSo(2) during the 60-minute period after cardiopulmonary bypass but not with other perfusion phas

107 l concentration occurred during surgery with cardiopulmonary bypass but was no longer present after c

108 es cardiac output after cardiac surgery with cardiopulmonary bypass, but a detailed analysis of its e

109 oronary artery bypass grafting surgery using cardiopulmonary bypass by 32 surgeons at 8 centers in no

110 Autoregulation was monitored during cardiopulmonary bypass by calculating a continuous, movi

111 thods of oxygenation and ventilation such as cardiopulmonary bypass can be used successfully to treat

112 ented with arterial and venous catheters and cardiopulmonary bypass cannulae) were randomized to conv

113 d by the Cockroft-Gault formula), undergoing cardiopulmonary bypass cardiac surgery.

114 with increased morbidity and mortality after cardiopulmonary bypass cardiac surgery.

115 patients with renal insufficiency undergoing cardiopulmonary bypass cardiac surgery.

116 oplegic arrest followed by reperfusion after cardiopulmonary bypass causes microvascular dysfunction

117 ventive surgical strategies (PSS: peripheral cardiopulmonary bypass, circulatory arrest, and non-medi

118 the extracorporeal membrane oxygenation and cardiopulmonary bypass cohorts was 45.4 (+/- 15.6) and 6

119 e coronary syndrome (ACS) patients requiring cardiopulmonary bypass (coronary artery bypass graft sur

120 Cardiopulmonary bypass-coronary artery bypass graft or d

121 cal dysfunction following reperfusion or the cardiopulmonary bypass-coronary artery bypass graft-indu

122 Cardioplegia and cardiopulmonary bypass (CP/CPB) subjects myocardium to c

123 tive, cardiac surgery using cardioplegia and cardiopulmonary bypass (CP/CPB) subjects myocardium to h

124 vs 28 (27-30) points; P = 0.021], length of cardiopulmonary bypass (CPB) [CPB; 133 (112-163) vs 119

125 hat leukocytes of patients with T2D or after cardiopulmonary bypass (CPB) expressed similar SI.

126 nt inhibitor of complement activation during cardiopulmonary bypass (CPB) has been shown to significa

127 ed before, during and after deep hypothermic cardiopulmonary bypass (CPB) in nine neonates.

128 We investigated the effects of cardiopulmonary bypass (CPB) on peripheral arteriolar re

129 We investigated the effects of cardiopulmonary bypass (CPB) on the contractile response

130 Cardiopulmonary bypass (CPB) provokes inflammation culmi

131 ciated with cerebral hypoxia-ischemia during cardiopulmonary bypass (CPB) remains limited, largely du

132 The use of cardiopulmonary bypass (CPB) results in the activation o

133 ecognized immune response to protamine after cardiopulmonary bypass (CPB) surgery with potential impo

134 The MHCA + SACP group had shorter cardiopulmonary bypass (CPB) time (146.9 +/- 40.6 vs 189

135 Data from 345 children after cardiopulmonary bypass (CPB) were analyzed.

136 We developed a porcine model of infant cardiopulmonary bypass (CPB) with deep hypothermic circu

137 nic artificial surfaces, for example, during cardiopulmonary bypass (CPB), induces a highly procoagul

138 reased in performing CABG without the use of cardiopulmonary bypass (CPB), to reduce postoperative co

139 s undergoing cardiac surgery with the use of cardiopulmonary bypass (CPB).

140 ed to reverse heparin anticoagulation during cardiopulmonary bypass (CPB).

141 ht reduce systemic inflammation induced by a cardiopulmonary bypass (CPB).

142 ne (S(Cr)) is a delayed marker for AKI after cardiopulmonary bypass (CPB).

143 m of vasodilatory shock that can occur after cardiopulmonary bypass (CPB).

144 e cardiac surgery with the implementation of cardiopulmonary bypass (CPB).

145 al coronary artery bypass grafting (CABG) on cardiopulmonary bypass (CPB).

146 coronary artery bypass grafting (CABG) using cardiopulmonary bypass (CPB).

147 h-risk females undergoing cardiac surgery on cardiopulmonary bypass (CPB).

148 20% to 40% of surgical procedures requiring cardiopulmonary bypass (CPB).

149 performing CABG both off-pump (OPCAB) and on cardiopulmonary bypass (CPB).

150 Harvesting did not affect cardiopulmonary bypass, cross-clamp, or surgical times.

151 ent of specially designed internal emergency cardiopulmonary bypass devices.

152 average mean arterial blood pressure during cardiopulmonary bypass did not differ, the mean arterial

153 y bypass and were associated (p < 0.01) with cardiopulmonary bypass duration (R = 0.22), depletion of

154 te analysis, baseline cholesterol levels and cardiopulmonary bypass duration were significant and ind

155 lve mean pressure gradient <40 mm Hg, longer cardiopulmonary bypass duration, and prosthesis-patient

156 ndergoing primary isolated CABG surgery with cardiopulmonary bypass during calendar year 2008 at 798

157 rposition approach to liver transplantation, cardiopulmonary bypass during liver transplantation in t

158 seline), at cardiopulmonary bypass start, at cardiopulmonary bypass end, and 3 and 24 hours after car

159 h-risk patients undergoing CABG surgery with cardiopulmonary bypass enrolled between October 2006 and

160 cal approach, and in providing a timely post-cardiopulmonary bypass evaluation of the procedure, ther

161 ficant bleeding and hypofibrinogenemia after cardiopulmonary bypass, fibrinogen concentrate is noninf

162 ading dose of study drug was administered on cardiopulmonary bypass followed by a continuous infusion

163 R or N-EPR, resuscitation was initiated with cardiopulmonary bypass for 60 mins and mechanical ventil

164 tween ages 1 month to 18 years who underwent cardiopulmonary bypass for cardiac surgery and survived

165 ey injury in infants and children undergoing cardiopulmonary bypass for cardiac surgery.

166 pulmonary bypass and 4, 24, and 48 hrs after cardiopulmonary bypass for measurement of plasma arginin

167 tive intraaortic balloon pumps, or return to cardiopulmonary bypass (for hemodynamic reasons).

168 ents undergoing CABG surgery with or without cardiopulmonary bypass from February 1, 2002, through Ma

169 ts having coronary bypass graft surgery with cardiopulmonary bypass from November 1996 to June 2000 a

170 acic surgery and a possible association with cardiopulmonary bypass heater-cooler units following ale

171 of reducing the inflammatory response after cardiopulmonary bypass; however, the value of this appro

172 as conducted to elucidate mechanisms of post-cardiopulmonary bypass immunosuppression.

173 onary bypass, and 2 hours and 24 hours after cardiopulmonary bypass in 60 subjects.

174 l improvements, including the development of cardiopulmonary bypass in the 1950s, large-scale repair

175 ronary-artery bypass grafting (CABG) without cardiopulmonary bypass in the elderly are still undeterm

176 among patients undergoing CABG surgery with cardiopulmonary bypass in US hospitals in an adult cardi

177 Changes in LV function at the conclusion of cardiopulmonary bypass included decreased stroke area (f

178 an effort to prevent deleterious effects of cardiopulmonary bypass, including the associated inflamm

179 tension or recipients who required prolonged cardiopulmonary bypass increased the risk for mortality.

180 ng coronary artery bypass graft surgery with cardiopulmonary bypass, increased atrial matrix metallop

181 indicates that immature WM is vulnerable to cardiopulmonary bypass-induced injury but has an intrins

182 eration was observed within a few days after cardiopulmonary bypass-induced ischemia-reperfusion inju

183 n this model, WM injury was identified after cardiopulmonary bypass-induced ischemia-reperfusion inju

184 ic arrest (CP) followed by reperfusion after cardiopulmonary bypass induces coronary microvascular dy

185 ardiogram, pulmonary artery catheterization, cardiopulmonary bypass, inhaled nitric oxide, and inhale

186 Cardiopulmonary bypass initiates a systemic inflammatory

187 ry bypass grafting performed with the use of cardiopulmonary bypass is a well-validated treatment for

188 Cardiac surgery with cardiopulmonary bypass is associated with mechanical man

189 Cardiopulmonary bypass is associated with severe immune

190 ng coronary artery bypass graft surgery with cardiopulmonary bypass, it reduced cardiac matrix metall

191 ergoing coronary artery bypass grafting with cardiopulmonary bypass, levosimendan compared with place

192 After cardiac surgery with cardiopulmonary bypass, levosimendan induces a vasodilat

193 sed sterile water for heater-cooler units of cardiopulmonary bypass machines.

194 levels before elective cardiac surgery with cardiopulmonary bypass may be a simple biomarker for the

195 In addition, the elimination of cardiopulmonary bypass may reduce the risk of short-term

196 % CI, 5.1-68.4; p = 0.001) with earlier post-cardiopulmonary bypass measures of uncertain utility.

197 extensive surgical procedures, avoidance of cardiopulmonary bypass, minimizing injury from radiocont

198 During initiation of cardiopulmonary bypass, MMP activity increased by 20% fr

199 of myocardial blood flow and separation from cardiopulmonary bypass, MMP interstitial activity increa

200 We developed a porcine cardiopulmonary bypass model that displays area-dependen

201 untreated animals) in a clinically relevant cardiopulmonary-bypass model in sheep.

202 lower quartile (< 9.2 pg/mL) at 4 hrs after cardiopulmonary bypass (n = 29), labeled group A, were e

203 -thoracotomy with peripheral cannulation for cardiopulmonary bypass (n=3907) were analyzed.

204 less than 18 years old, procedures requiring cardiopulmonary bypass, no preexisting renal dysfunction

205 imary outcome when measured 18-24 hours post-cardiopulmonary bypass (odds ratio, 18.6; 95% CI, 5.1-68

206 C transfusion during surgery and duration of cardiopulmonary bypass (odds ratio, 2.98; 95% CI, 1.96-4

207 cardiopulmonary bypass (on pump) or without cardiopulmonary bypass (off pump).

208 CABG without cardiopulmonary bypass (off-pump CABG) might reduce the

209 CABG to undergo the procedure either without cardiopulmonary bypass (off-pump CABG) or with it (on-pu

210 e effect of MR reduction without surgery and cardiopulmonary bypass on left ventricular (LV) dimensio

211 (CABG) surgery may be performed either with cardiopulmonary bypass (on pump) or without cardiopulmon

212 technique (off-pump CABG), as compared with cardiopulmonary bypass (on-pump CABG), are not clearly e

213 traditionally been performed with the use of cardiopulmonary bypass (on-pump CABG).

214 CABG was performed with or without cardiopulmonary bypass (on-pump vs. off-pump surgery) ac

215 and those who underwent CABG performed with cardiopulmonary bypass (on-pump).

216 ement of patients requiring procedures using cardiopulmonary bypass or interventions in the catheteri

217 olytic drugs for use in cardiac surgery with cardiopulmonary bypass or organ transplantations to redu

218 olytic drugs for use in cardiac surgery with cardiopulmonary bypass or organ transplantations to redu

219 e use in the context of failure to wean from cardiopulmonary bypass or use to avoid cardiopulmonary b

220 (OR, 2; 95% CI, 1.2-3.3; P = 0.008); use of cardiopulmonary bypass (OR, 3.4; 95% CI, 2.2-5.3; P < 0.

221 thetic induction and 250 mg at initiation of cardiopulmonary bypass) or placebo.

222 y after transplant surgery performed without cardiopulmonary bypass (P for interaction = 0.03).

223 ts who underwent elective cardiac surgery on cardiopulmonary bypass, paired samples of the right atri

224 Thrombocytopenia increased in cardiopulmonary bypass patients on day 2 but was normal

225 atically increased arginase-1 levels in post-cardiopulmonary bypass peripheral blood mononuclear cell

226 f myeloid-derived suppressor cells from post-cardiopulmonary bypass peripheral blood mononuclear cell

227 After cardiopulmonary bypass, peripheral blood mononuclear cel

228 In patients undergoing cardiopulmonary bypass, plasma KIM-1 levels increased wi

229 near horizon is the combination of advanced cardiopulmonary bypass plus a cocktail of multiple agent

230 WMI was also associated with the duration of cardiopulmonary bypass, postoperative lactate level, bra

231 corporeal cardiopulmonary resuscitation with cardiopulmonary bypass potentially provides cerebral rep

232 cardiac surgery, since it is recognized that cardiopulmonary bypass presents many precipitating risk

233 -associated lipocalin measured 3 hours after cardiopulmonary bypass provided excellent early risk str

234 a cardiovascular surgeon, perfusionist, and cardiopulmonary bypass pump facilitates lifesaving repai

235 ion of haptoglobin at end and 24 hours after cardiopulmonary bypass (R = 0.12 and 0.15, respectively)

236 tively), lactate dehydrogenase levels at end cardiopulmonary bypass (R = 0.27), and change in creatin

237 T1 correlated with RV T1 (r=0.45, P<0.001), cardiopulmonary bypass (r=0.30, P=0.007), and aortic cro

238 In anaesthetized dogs connected to cardiopulmonary bypass, reflexogenic areas of the caroti

239 tively low at baseline and remains low after cardiopulmonary bypass regardless of hemodynamic stabili

240 Particularly, a cardiopulmonary bypass-related long-lasting immunosuppre

241 eline and after 20 min CA followed by 30 min cardiopulmonary bypass resuscitation.

242 ia-induced cardiac arrest followed by 30 min cardiopulmonary bypass resuscitation.

243 tive therapies such as cricothyroidotomy and cardiopulmonary bypass should be available if first-line

244 s before anesthesia induction (baseline), at cardiopulmonary bypass start, at cardiopulmonary bypass

245 in was 4.9 +/- 2.6 in group A at 4 hrs after cardiopulmonary bypass, statistically unchanged from its

246 Cardiopulmonary bypass strongly impairs the adaptive imm

247 Cardiopulmonary bypass surgery (CPB) is associated with

248 tinal bleeding is common following pediatric cardiopulmonary bypass surgery for congenital heart dise

249 Of 591 patients undergoing cardiopulmonary bypass surgery, 57 (9.6%) tested positiv

250 led trial on infants 2.5 to 12 kg undergoing cardiopulmonary bypass surgery, aimed at (1) demonstrati

251 a, such as that induced by cardiac arrest or cardiopulmonary bypass surgery, causes cell death in vul

252 levant condition of systemic sterile stress, cardiopulmonary bypass surgery, we confirmed the initial

253 e 2 diabetes mellitus and patients following cardiopulmonary bypass surgery.

254 RT/H antibodies occur in patients undergoing cardiopulmonary bypass surgery.

255 or acute insulin resistance associated with cardiopulmonary bypass surgery.

256 METHODS AND Under cardiopulmonary bypass, the papillary muscle tips in 6 a

257 Under cardiopulmonary bypass, the papillary muscle tips in 6 s

258 ts with congenital heart disease who undergo cardiopulmonary bypass, those who receive extracorporeal

259 corporeal membrane oxygenation compared with cardiopulmonary bypass throughout (p < 0.0001).

260 = 2.4), hemodynamic instability (OR = 2.8), cardiopulmonary bypass time >120 minutes (OR = 6.2), per

261 ergency status (P=0.006), rupture (P=0.004), cardiopulmonary bypass time >120 minutes (P<0.04), and p

262 e 139.8] versus 412.8 [132] min, P < 0.001), cardiopulmonary bypass time (220 [63] versus 176 [73] mi

263 ood operation (HR, 2.3; P=0.001), and longer cardiopulmonary bypass time (HR, 1.1 per 10 minutes; P=0

264 Cardiopulmonary bypass time and age were independently a

265 A surgical strategy to minimize cardiopulmonary bypass time is critical for these challe

266 Cardiopulmonary bypass time may be a marker for case com

267 prised 72% of procedures and had a mean (SD) cardiopulmonary bypass time of 200 minutes (83) minutes.

268 In the CABG group, cardiopulmonary bypass time or days in intensive care di

269 Longer cardiopulmonary bypass time was linearly and independent

270 Cardiopulmonary bypass time was the only independent sur

271 analysis, age more than 65 years, prolonged cardiopulmonary bypass time, and severe pulmonary hypert

272 r resistance index, graft ischemic time, and cardiopulmonary bypass time, donor low-dose dopamine was

273 included pre-operative diuretic use, longer cardiopulmonary bypass time, operation prior to 1991, at

274 Men experienced longer cross-clamp and cardiopulmonary bypass times, but similar durations of c

275 ve coronary artery bypass graft surgery with cardiopulmonary bypass to determine whether doxycycline

276 h the presentation, blood loss, and need for cardiopulmonary bypass to facilitate repair.

277 s undergoing cardiac surgery with the use of cardiopulmonary bypass to receive either methylprednisol

278 ntricular shape change device placed without cardiopulmonary bypass to reduce FMR.

279 duled for elective cardiac surgery requiring cardiopulmonary bypass under total anesthesia with intra

280 justing for pretransplantation lung disease, cardiopulmonary bypass use, and population stratificatio

281 of 31 patients (61%); the median duration of cardiopulmonary bypass was 19 minutes.

282 Median duration of cardiopulmonary bypass was 4.6 hours (2-16.5 hr) compare

283 patients had a moderate or large injury, and cardiopulmonary bypass was required in 13 patients with

284 There were 34 patients in whom cardiopulmonary bypass was used (7.6%), 17 conversions t

285 Cardiopulmonary bypass was used for 19 of 31 patients (6

286 a in extracorporeal membrane oxygenation and cardiopulmonary bypass were 6.4% (19/298) and 0.6% (18/2

287 ral blood mononuclear cells before and after cardiopulmonary bypass were analyzed for the expression

288 lack of mitral annuloplasty, and duration of cardiopulmonary bypass were associated with increased ri

289 ombined coronary artery bypass grafting with cardiopulmonary bypass were enrolled from June 2013 unti

290 Patients who had had cardiac surgery with cardiopulmonary bypass were enrolled.

291 gth of intensive care unit stay, and time on cardiopulmonary bypass were secondary outcomes.

292 ient >20 mm Hg) and prolonged intraoperative cardiopulmonary bypass were significant risk factors for

293 chemical pleurodesis procedure and prolonged cardiopulmonary bypass were significantly associated wit

294 autoregulation threshold (mm Hg x min/hr of cardiopulmonary bypass) were both higher in patients wit

295 ystemic inflammatory response to surgery and cardiopulmonary bypass, which in turn may mediate prolon

296 531 patients undergoing cardiac surgery with cardiopulmonary bypass who had a moderate-to-high risk o

297 cases of aortic aneurysm repair, 7 involving cardiopulmonary bypass with deep hypothermic circulatory

298 ing antegrade cerebral perfusion, the use of cardiopulmonary bypass with mild hypothermia, and the in

299 cheduled for routine cardiac procedures with cardiopulmonary bypass without documented dementia were

300 c subgroups of pediatric patients undergoing cardiopulmonary bypass would benefit from potential trea